• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec18
Positive Zasocitinib Clinical Trial Data from Takeda Catalyzes New Era in Psoriasis Treatment
08:02
Nov7
Takeda Publishes New Data on Mezagitamab for IgA Nephropathy
16:01
Oct30
Takeda Pharmaceutical Company released FY2026 Semi-Annual Earnings on October 30 After-Market EST, actual revenue USD 15.13 B (forecast USD 15.48 B), actual EPS USD 0.2401
23:00
Takeda Pharmaceutical Company released FY2026 Q2 earnings on October 30, 2025, after-market EST: Actual Revenue USD 7.487 B (Forecast USD 7.97 B), Actual EPS USD -0.0251
23:00
Takeda Pharmaceutical Sees 40% Drop in Net Profit in First Half of 2023
09:21
Oct23
Takeda Pharmaceutical Company to Release FY2026 Q2 Earnings on October 30 After-Market EST, Forecast Revenue USD 7.757 B
00:08

Schedules & Filings

Schedules
Filings
Jan29
Earning Release(EST)

FY2026 Q3 Earning Release

Oct30
Earning Release(EST)

FY2026 Q2 Earning Release (USD) Revenue 7.487 B, Net Income -79.4 M, EPS -0.0251

Sep30
Distribution Plan(EST)

Cash dividend 0.3459 USD

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SOBR
2.370
+82.31%
+1.070
OMER
15.360
+75.54%
+6.610
NCL
0.2560
+49.45%
+0.085
AMCI
9.350
+47.94%
+3.030
EUDA
2.770
+44.27%
+0.850
DVAX
15.380
+38.19%
+4.250
MWG
0.3496
+38.13%
+0.097
INDP
2.650
+35.90%
+0.700
SIDU
2.200
+33.33%
+0.550
FMFC
0.3929
+28.74%
+0.088
View More